Timi3 Systems


Public lists: Pharma Startups (4743)

Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of thrombolytic drugs that hasten the dissolution of thrombus during a myocardial infarction. Timi3 Systems, Inc. was founded in 1999 and is based in Santa Clara, California.

Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of ...Show all

Company (Alive / Active)

Phone: 408-566-0780

Fax:

3032 Coronado Drive

Santa Clara, 95054
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Timi3 Systems $16.4M Dec 23, 2008
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Timi3 Systems Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 3 investors

Board Members

Competitors

Company Status Description Investors

Bioheart

Sunrise, Florida, United States
Alive / ActiveBioheart is a biotechnology company focused on the discovery, development, and commercialization of cell therapies for the treatment of chronic and acute heart damage.Login to see details

Cellerant Therapeutics

San Carlos, California, United States
Alive / ActiveCellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia,...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)